ACCESS Newswire
09 Sep 2019, 18:01 GMT+10
HACKENSACK, NJ / ACCESSWIRE / September 9, 2019 / Champions Oncology, Inc. (NASDAQ:CSBR), engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs, today announced it will report its financial and operational results for the first quarter ended July 31, 2019, on Monday, September 16, 2019, after market close.
The company will host a conference call to discuss the results that day at 4:30 p.m. EDT (1:30 p.m. PDT). To participate in the call, please call 844-602-0380 (domestic) or 862-298-0970 (international) ten minutes ahead of the call and give the verbal reference 'Champions Oncology.'
A replay of the call will be available by dialing 877-481-4010 and entering Passcode:53656, or by accessing the Investor tab of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology, Inc. is engaged in an end-to-end range of research and development technology solutions and services to improve the development and use of oncology drugs. The Company's TumorGraft technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions primarily in Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.
Investor Contacts:
David Miller
CFO
Champions Oncology, Inc
(551) 206-8104
[email protected]
SOURCE: Champions Oncology, Inc.
Get a daily dose of St Louis Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to St Louis Star.
More InformationWASHINGTON, D.C.: In a challenge to California's push for cleaner transportation, the U.S. House of Representatives voted this week...
CHICAGO, Illinois: The Chicago and Cook County health departments say that two people in Cook County have measles. These are the...
WASHINGTON, D.C.: The Trump administration through U.S. Environmental Protection Agency (EPA) is canceling nearly 800 grants, including...
I will never forget that fateful moment when I was just 11 years old, walking back home from school with my friend. Unfortunately,...
SYDNEY, NSW, Australia - The Australian Labor Party has been swept to victory for a second term after defeating the Coalition in an...
WASHINGTON, D.C.: The U.S. State Department has started a second round of its deferred resignation program, according to an internal...
SEATTLE, Washington: Starbucks is shifting course on its store strategy—putting people ahead of machines. The coffee giant announced...
BEIJING, China: China's manufacturing sector lost steam in April, with activity shrinking at the fastest pace in over a year, as new...
SYDNEY, Australia: A key measure of inflation in Australia has cooled to its lowest level in three years, lending weight to expectations...
DUBLIN, Ireland: April 2025 saw a slight improvement in the labor market, with the seasonally adjusted unemployment rate dropping to...
LONDON, U.K.: Grocery prices in the UK rose by 3.8 percent in April, slightly higher than last month's 3.5 percent, adding more pressure...
HONG KONG: Hong Kong's housing market continued to lose ground in March, with home prices falling for a fourth straight month despite...